Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
After finishing at $50.01 in the prior trading day, Soleno Therapeutics Inc (NASDAQ: SLNO) closed at $50.0, down -0.02%. In other words, the price has decreased by -$0.02 from its previous closing price. On the day, 1.32 million shares were traded. SLNO stock price reached its highest trading level at $50.51 during the session, while it also had its lowest trading level at $49.57.
Ratios:
Our goal is to gain a better understanding of SLNO by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 15.88 and its Current Ratio is at 16.08. In the meantime, Its Debt-to-Equity ratio is 0.11 whereas as Long-Term Debt/Eq ratio is at 0.11.
Upgrades & Downgrades
In the most recent recommendation for this company, Wolfe Research on November 18, 2025, initiated with a Outperform rating and assigned the stock a target price of $75.
On October 07, 2025, Goldman started tracking the stock assigning a Buy rating and target price of $125.
On August 20, 2025, Wells Fargo started tracking the stock assigning a Overweight rating and target price of $123.Wells Fargo initiated its Overweight rating on August 20, 2025, with a $123 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Aug 11 ’25 when Abingworth Bioventures VII LP bought 1,347,522 shares for $82.15 per share.
Hirano Patricia C sold 3,830 shares of SLNO for $316,971 on Jul 01 ’25. The insider now owns 13,206 shares after completing the transaction at $82.76 per share. On Jul 01 ’25, another insider, PATRICIA HIRANO, who serves as the Officer of the company, bought 3,830 shares for $82.76 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, SLNO now has a Market Capitalization of 2685501184 and an Enterprise Value of 2239230208. For the stock, the TTM Price-to-Sale (P/S) ratio is 27.22 while its Price-to-Book (P/B) ratio in mrq is 5.43. Its current Enterprise Value per Revenue stands at 22.693 whereas that against EBITDA is -27.222.
Stock Price History:
The Beta on a monthly basis for SLNO is -3.13, which has changed by 0.08059633 over the last 52 weeks, in comparison to a change of 0.13042927 over the same period for the S&P500. Over the past 52 weeks, SLNO has reached a high of $90.32, while it has fallen to a 52-week low of $41.50. The 50-Day Moving Average of the stock is -11.58%, while the 200-Day Moving Average is calculated to be -25.46%.
Shares Statistics:
The stock has traded on average 2.13M shares per day over the past 3-months and 1525330 shares per day over the last 10 days, according to various share statistics. A total of 53.70M shares are outstanding, with a floating share count of 49.30M. Insiders hold about 8.21% of the company’s shares, while institutions hold 117.16% stake in the company. Shares short for SLNO as of 1764288000 were 9093766 with a Short Ratio of 4.28, compared to 1761868800 on 8484772. Therefore, it implies a Short% of Shares Outstanding of 9093766 and a Short% of Float of 19.299999.
Earnings Estimates
The performance of Soleno Therapeutics Inc (SLNO) in the stock market is under the watchful eye of 13.0 analysts actively contributing to its current rating.The consensus estimate for the next quarter is $0.69, with high estimates of $1.08 and low estimates of $0.23.
Analysts are recommending an EPS of between $0.74 and -$0.24 for the fiscal current year, implying an average EPS of $0.18. EPS for the following year is $4.06, with 13.0 analysts recommending between $5.78 and $1.78.
Revenue Estimates
For the next quarter, 11 analysts are estimating revenue of $89.4M. There is a high estimate of $108.18M for the next quarter, whereas the lowest estimate is $73.8M.
Based on 11 analysts’ estimates, the company’s revenue will be $461.65M in the next fiscal year. The high estimate is $563.14M and the low estimate is $351.6M.
